Eli Lilly has unveiled early clinical results from its Ajax Therapeutics acquisition at the European Hematology Association (EHA) 2026 meeting, showing strong activity of a next-generation JAK2 inhibitor in patients with myelofibrosis who had already failed prior therapies. The data
